EUVIMEDEUVIMED entdecken
Open Access

PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging

Adrien Holzgreve, Wesley R Armstrong, Kevyn J Clark, Matthias R Benz, Clayton P Smith, Loïc Djaileb, Andrei Gafita, Pan Thin, Nicholas G Nickols, Amar U Kishan, Matthew B Rettig, Robert E Reiter und 2 weitere

JAMA Network Open · 03.01.2025 · 8 (1) · e2452971

DOI: 10.1001/jamanetworkopen.2024.52971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 03.01.2025. Verfasst von Adrien Holzgreve und 13 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of Califo…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Neoplasm Recurrence, Local, Prostate-Specific Antigen. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen–positron emission tomography (PSMA-PET).

Objective

To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial. Design, Setting, and Participants This post hoc, retrospective cross-sectional study included 182 patients from 4 prospective studies conducted from September 15, 2016, to September 27, 2021. All patients had recurrent prostate cancer after radical prostatectomy (RP), definitive radiotherapy (dRT), or salvage radiotherapy (SRT). Analysis was performed from January 2023 to July 2024. Exposures Patients included had increasing prostate-specific antigen (PSA) levels greater than 1.0 ng/mL (after RP and SRT) or 2.0 ng/mL above the nadir value (after dRT), PSA doubling time of 9 months or less, and a serum testosterone level of 150 ng/dL or greater. Exclusion criteria were distant metastatic disease on radiographic imaging and prior hormonal or systemic therapy. Main Outcomes and Measures Staging information obtained by PSMA-PET/CT in patients with nonmetastatic disease according to conventional imaging.

Results

From 2002 patients screened, 182 (median age at PET/CT scan, 69 years [IQR, 64-73 years]) were included. Median prescan PSA levels were 2.4 ng/mL (IQR, 1.4-4.8 ng/mL) after RP (n = 91), 6.9 ng/mL (IQR, 3.5-18.5 ng/mL) after dRT (n = 39), 2.6 ng/mL (IQR, 1.6-5.2 ng/mL) after RP and SRT (n = 52), and 2.8 ng/mL (IQR, 1.7-6.6 ng/mL) overall (n = 182). Results of PSMA-PET were positive in 80% of patients (73 of 91) after RP, 92% of patients (36 of 39) after dRT, 85% of patients (44 of 52) after RP and SRT, and 84% of patients (153 of 182) overall. PSMA-PET detected any distant metastatic disease (miTxNxM1) in 34% of patients (31 of 91) after RP, 56% of patients (22 of 39) after dRT, 60% of patients (31 of 52) after RP and SRT, and 46% of patients (84 of 182) overall. Polymetastatic disease (≥5 lesions) was found in 19% of patients (17 of 91) after RP, 36% of patients (14 of 39) after dRT, 23% of patients (12 of 52) after RP and SRT, and 24% of patients (43 of 182) overall. Conclusions and Relevance In a cohort of patients with high-risk hormone-sensitive prostate cancer without evidence of metastatic disease by conventional imaging, PSMA-PET results were positive in 84% of patients, detected M1 disease stage in 46% of patients, and found polymetastatic disease (≥5 lesions) in 24% of patients, suggesting that patients’ high-risk nonmetastatic hormone-sensitive prostate cancers are understaged by conventional imaging. The results challenge the interpretation of previous studies, such as the EMBARK trial, and support the evolving role of PSMA-PET for patient selection in clinical and trial interventions in prostate cancer. Further studies are needed to assess its independent prognostic value and use for treatment guidance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsNeoplasm Recurrence, LocalProstate-Specific AntigenHumansMaleAgedMiddle AgedRetrospective StudiesCross-Sectional StudiesAntigens, SurfaceNitrilesPhenylthiohydantoinNeoplasm StagingLeuprolideGlutamate Carboxypeptidase IIBenzamides

Substanzen

Prostate-Specific AntigenFOLH1 protein, humanAntigens, SurfaceNitrilesenzalutamidePhenylthiohydantoinLeuprolideGlutamate Carboxypeptidase IIBenzamides

Autor:innen und Institutionen

  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
  • Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • ULCA-Caltech Medical Scientist Training Program, David Geffen School of Medicine, Los Angeles, California.
  • Department of Radiological Sciences, University of California, Los Angeles.
  • Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany.
  • Jonsson Comprehensive Cancer Center, University of California, Los Angeles.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Holzgreve, A., Armstrong, W. R., Clark, K. J., Benz, M. R., Smith, C. P., Djaileb, L., Gafita, A., Thin, P., Nickols, N. G., Kishan, A. U., Rettig, M. B., Reiter, R. E., Czernin, J., & Calais, J. (2025). PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Network Open, 8(1), e2452971. https://doi.org/10.1001/jamanetworkopen.2024.52971

Vancouver

Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, et al. PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Network Open. 2025;8(1):e2452971. doi:10.1001/jamanetworkopen.2024.52971

BibTeX
@article{Holzgreve2025,
  author = {Holzgreve, Adrien and Armstrong, Wesley R and Clark, Kevyn J and Benz, Matthias R and Smith, Clayton P and Djaileb, Loïc and Gafita, Andrei and Thin, Pan and Nickols, Nicholas G and Kishan, Amar U and Rettig, Matthew B and Reiter, Robert E and Czernin, Johannes and Calais, Jeremie},
  title = {PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {1},
  pages = {e2452971},
  doi = {10.1001/jamanetworkopen.2024.52971}
}
Kostenlos starten →